Health Economics

Cost Effectiveness

Cost-effectiveness analysis is an increasingly important tool for healthcare decision-making in the context of increasing budgetary constraints, an ever-increasing range of treatment options, and the relatively high price of new treatments.1-3

THERAKOS ECP ImmunomodulationTM has been shown to be a cost-effective treatment for acute and chronic graft-versus-host disease, cutaneous T-cell lymphoma (CTCL), and chronic lung allograft dysfunction-bronchiolitis obliterans syndrome (CLAD-BOS).3-8

In addition, studies show that THERAKOS ECP ImmunomodulationTM may help to minimise the costs associated with immunosuppressing the patient.3,4

Cost effectiveness in
acute GvHD

In acute GvHD, THERAKOS ECP ImmunomodulationTM has shown cost-effectiveness in adults7

Cost effectiveness in
chronic GvHD

In chronic GvHD, THERAKOS ECP ImmunomodulationTM has shown cost-effectiveness in adults3,5,7


In CTCL, THERAKOS ECP ImmunomodulationTM has shown cost-effectiveness in adults6


In CLAD-BOS, THERAKOS ECP ImmunomodulationTM 
has shown cost-effectiveness in adults8

BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; ECP, extracorporeal photopheresis; CTCL, cutaneous T-cell lymphoma; GvHD, graft-versus-host disease.

1. Hill SR. BMC Med. 2012;10:10; 2. Eichler HG, et al. Value Health. 2004;7(5):518-528; 3. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787; 4. Walczak J, et al. Value Health. 2012;15:A349; 5. de Waure C, et al. Value Health. 2015;18(4):457-466; 6. Geskin L, Malone DC. J Dermatolog Treat. 2018;29(5):522-530. 7. Wepsięć K, et al. Cost-effectiveness analysis of extracorporeal photopheresis (procedure TherakosTM) in the treatment of steroid-refractory graft versus host disease. Kraków (Poland): Instytut Arcana; 2012. 80 p. 8. Zia A, et al. Value Health PRS14. 2019;22(2):S351. 9. Jaksch P, et al. J Heart Lung Transpl. 2012;38(4S). 10. Benden C, et al. J Heart Lung Transpl. 2017;36:921-933.